BMI vs FROG

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating marginal financial health, and the absence of an Altman Z-Score prevents a full solvency risk assessment. Despite solid profitability metrics like 21.45% ROE and 19.57% operating margin, elevated valuation (P/E of 36.77 vs. sector average of 84.87) and bearish technical trend (0/100) offset strength in fundamentals. Revenue and earnings growth remain positive at 13.1% and 10.2% YoY, but recent price performance is sharply negative (-22% over 1Y), and analyst target suggests upside to $211.30. The stock trades well above the Graham Number of $49.73, reflecting premium pricing for growth expectations despite mixed earnings surprise trends.

FROG presents a dichotomy between strong growth fundamentals and concerning internal sentiment. The company maintains a stable financial health profile with a Piotroski F-Score of 5/9 and a pristine balance sheet (Debt/Equity of 0.01), though it remains GAAP unprofitable with a -13.50% profit margin. While revenue growth is robust at 25.20% and earnings consistently beat estimates, the bearish insider signal (CEO/CFO selling) and a 0/100 technical trend offset the 'Strong Buy' analyst consensus. The stock is currently valued as a high-growth asset, trading at a premium P/S ratio of 10.13.